IC
APLS

Ikarian Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Ikarian Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-71,747
Closed -$1.8M – 169
2025
Q4 		$1.8M Sell
71,747
-380,155
-84% -$8.92M 0.14% 106
2025
Q3 		$10.2M Buy
451,902
+376,902
+503% +$8.79M 1.03% 26
2025
Q2 		$1.3M Hold
75,000
– – 0.25% 76
2025
Q1 		$1.64M Buy
75,000
+71,406
+1,987% +$1.97M 0.2% 74
2024
Q4 		$115K Buy
+3,594
New +$108K 0.02% 154
2024
Q2 		– Sell
-35,092
Closed -$2.06M – 117
2024
Q1 		$2.06M Buy
35,092
+731
+2% +$46.6K 0.23% 87
2023
Q4 		$2.06M Buy
+34,361
New +$1.74M 0.19% 84
2023
Q3 		– Sell
-133,800
Closed -$5.88M – 142
2023
Q2 		$12.2M Buy
133,800
+33,800
+34% +$2.92M 1.94% 11
2023
Q1 		$6.6M Buy
+100,000
New +$5.77M 1.5% 20
2022
Q3 		– Sell
-41,900
Closed -$1.89M – 111
2022
Q2 		$1.89M Buy
+41,900
New +$1.91M 0.35% 59
2021
Q4 		– Sell
-347,545
Closed -$13.7M – 189
2021
Q3 		$11.5M Buy
+347,545
New +$19.5M 0.81% 31
2020
Q4 		– Sell
-18,726
Closed -$565K – 233
2020
Q3 		$565K Buy
18,726
+16,600
+781% +$496K 0.04% 139
2020
Q2 		$69K Sell
2,126
-50,000
-96% -$1.61M 0.01% 158
2020
Q1 		$1.4M Buy
52,126
+52,073
+98,251% +$1.85M 0.11% 108
2019
Q4 		$2K Buy
+53
New +$1.47K ﹤0.01% 114

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Ikarian Capital's APLS Position: Q1 2026 in Review

Ikarian Capital sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 71,747 shares — an estimated $1.8M sold.

Ikarian Capital first reported a position in APLS in Q4 2019 and held it in 15 quarters. The position peaked at $12.2M in Q2 2023. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Ikarian Capital reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 71,747 Apellis Pharmaceuticals shares in Q1 2026, an estimated $1.8M.
  • Ikarian Capital first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 15 quarters.
  • Ikarian Capital's Apellis Pharmaceuticals position peaked at $12.2M in Q2 2023.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.